The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Metastatic osteosarcoma (OS) has a poor prognosis with limited therapeutic advancements.
• Novel molecular targets are crucial for improving treatment outcomes in refractory OS.
• The Fas/FasL pathway presents a potential therapeutic target for osteosarcoma.

Purpose of the Study:

• To investigate the potential of modulating the Fas/FasL pathway for treating refractory osteosarcoma.
• To evaluate the efficacy of combining gemcitabine and entinostat in upregulating Fas expression on OS cells.

Main Methods:

• Preclinical data suggests Fas expression inversely correlates with OS metastatic potential.
• FasL in the lung induces cell death in OS cells expressing Fas.
• Gemcitabine and entinostat (HDAC inhibitor) upregulate Fas expression on OS cells.

Main Results:

• Upregulation of Fas expression on osteosarcoma cells is a key mechanism.
• Targeting the Fas/FasL pathway may decrease pulmonary metastasis of OS.
• Improved outcomes are anticipated with this therapeutic strategy.

Conclusions:

• Modulating the Fas/FasL pathway offers a promising strategy for refractory osteosarcoma.
• Combination therapy with gemcitabine and entinostat is under clinical investigation.
• This approach holds potential for improving survival in patients with metastatic OS.